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Abstract 
BACKROUND: The reversation of NMBA (neuromuscular blocking agents) prevents numerous postoperative 
complications, increases quality of recovery and decreases the time, expenditure spending in hospital. The choice 
of medicine used to reverse NMBA depends  considered as a key fators to gain the best outcome and to avoid the 
side effects. 
AIM: To evaluate the postoperative effect on muscle relaxation reversal and side effects of sugammadex 2 mg/kg 
versus the combination of  neostigmine and atropine sulfate in the living kidney donors.  
METHODS: A randomised controlled trial on 70 patients undergoing living kidney donation surgery were allocated 
to 2 groups. Patients in group I (SUGA) were reversed with sugammadex 2 mg/kg and in group II (NEO/ATR) with 
the combination of neostigmine and atropine sulfat. 
RESULTS: With 35 patients in each group, the study results showed that after 3 mintutes of reversal patients 
reaching TOF value ≥ 0.9 in group SUGA is 91.4%, after 5 minutes 100% of patients in group SUGA reached 
TOF value ≥ 0.9 . In group NEO/ATR after 3 minutes 28.6% patients reached TOF ≥ 0.9 and 40% patients 
reached TOF≥ 0.9 after 5 minutes. The difference in percentage of patients reaching TOF ≥ 0.9 after 3 minutes, 5 
minutes of reversal between two groups is significant (p<0.05). After 10 minutes, 100% patients in both group got 
TOF ≥ 0.9. Time to exutubation of group SUGA was 249.43 ± 81.75 seconds and it was 456.29 ± 146.45 seconds 
in group NEO/ATR. Nausea, bradycardia, and increased phlegm production in group NEO/ATR was 22.9%; 
28.5%; 25.7% respectively; while those side effects were not met in group SUGA, the difference was significant 
(p<0.05). 
CONCLUSION: The muscle relaxation reversal effect of sugammadex was faster than that of neostigmine, the 
duration TOF ≥ 0.9 and the time to extubation was significantly faster. Sugammadex did not cause hemodynamic 
changes before and after muscle relaxation reversal, neostigmine resulted in the bradycardia, increased phlegm 
secreting and other side effects. The renal function after 24 hours postoperatively of two groups was similar. 
 
 
Introduction 
 
 Nowadays, living donor nephrectomy in Viet 
Nam is usually performed under laparascopic 
methods, due to numerous advantages for the donors 
such as reduced blood loss, decreased tissue trauma, 
lower analgesia requirement, faster resumption of 
food and drinks intake, shorter hospitalisation and 
better postoperative cosmetic appearance. However, 
increasing abdominal pressure due to 
pneunoperitonium can affect the kidney function by 
impairing renal perfusion flow and does not facilitate 
surgeon’s procedure [1]. Therefore, profound 
neuromuscular blockade plays essential role in 
limitting the increase in abdominal pressure and 
facilitating surgical field for kidney removal. 
Postoperative residual curarization is a common 
complication after surgery that impacts the patient's 
safety. Postoperative residual curarization reduces 
ventilation response to hypoxia; induces laryngeal 
muscle and esophageal sphincter dysfunction which 
causes reflux, choking lungs; thus increasing risk of 
postoperative respiratory complications. Therefore, 
finding a safe way to reverse muscles relaxation is 
fundamental to achieving successful outcomes of 
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surgery. Neostigmine is a common neuromuscular 
blockade reversal agent; with anticholinesterase 
mechanism which allows acetylcholine to build up at 
the neuromuscular junction and subsequently results 
in competitively inhibiting non-depolarizing blocking 
drugs at the nicotinic receptor of motor nerve 
terminals. On the other hand, this drug simultaneously 
acts on muscarinic receptor that leads to several side 
effects, so neostigmine is frequently used with 
anticholinergic drugs such as atropine. The dose of 
neostigmine should be adjusted according to TOF 
count, and postoperative residual curarization may still 
exist after neostigmin administration [2], [3]. If 
neostigmine is used when TOF < 0.9, it may also 
increase the residual neuromuscular blockade [4], [5], 
[6]. Sugammadex, a cyclodextrin, is thought to be an 
antagonist - a selective relaxant-binding agent 
(SRBA), which reverses the aminosteroid group like 
rocuronium through an encapsulating mechanism to 
form a rigid sugammadex-rocuronium complex and 
then excreted in urine. Sugammadex has some 
advantages such as allowing reversal of profound 
blockade, rapid onset as well as no muscarinic side 
effects and no atropine combination requirement [7], 
[8], [9]. Dose of sugammadex and neostigmin chosen 
for reversal are based on TOF value [10]. In the world, 
there are several studies demonstrating the safety 
and efficacy of sugammadex and comparing the 
neuromuscular blockade reversal effect of 
sugammadex versus that of neostigmine.  
 An analyzed randomized controlled trial on 
the reversal function of sugammadex and neostigmine 
conducted by M.Carron et al in 2016 shows that in 
comparison to neostigmine, sugammadex reverses 
the neuromuscular block faster (p < 0.0001), has a 
stronger relation to TOF during extubation period, and 
decreases risk of recurarization after endotracheal 
tube withdrawing (OR = 0.05, CI 95%: 0.01 – 0.43; p = 
0.0068). Sugammasex also has a significant relation 
to reduction of all complications (p < 0.00016) [1]. 
 In Vietnam, there have been rare studies 
comparing the reversal effectiveness and side effects 
between sugammadex and the combination of 
neostigmine and atropine, especially on patients 
experiencing living donor nephrectomy. For that 
reason, we conducted this study to evaluate the 
differences in efficacy, undesirable effects between 
sugammadex 2 mg/kg and the combination of 
neostigmine and atropine at different doses and 
atropine sulfate in the living kidney donors. 
 
 
Materials and Methods 
 
 Criteria for selection 
- Age 18-60 years old, ASA I - III. 
- Laparocopic donor nephrectomy. 
- General anesthesia. 
- Normal results of complete blood count, 
physiochemical tests, echocardiogram. 
-  Surgery duration > 60 minutes. 
 
 Criteria for exclusion 
- Patient’s disagreement to participate in study. 
- Patients did not meet selection requirement. 
- Patients who have renal or hepatic 
dysfunction. 
- Patients having history of malignant 
hyperthermia or neuromuscual diseases. 
- Patients with difficult airway. 
- Prolonged diabetes patients with 
complication, neurological complication. 
- Patients with BMI < 17 kg/m
2
 or > 30 kg/m
2
. 
- Patients taking medications interacting with 
neuromuscular relaxants such as anticonvulsants, 
magnesium, and some antibiotics. 
- Patients having allergy to opioid, NMBA, 
anesthetics. 
 
 Patients rejected from study  
- Patients had allergy to medications, or 
anaphylaxis shock to anesthetics. 
- Patients with surgical complications. 
- Patients had postoperative severe condition 
which required treatment in ICU and mechanical 
ventilation > 24h. 
 
 Study methods 
 This study was a single blinded randomized 
controlled trial. Patients were allocated to 2 groups: 
- Group I (SUGA) : Sugammadex 2 mg/kg were 
used to reverse NMBA. 
- Group II (NEO/ATR): Different doses of 
neostigmine combined with atropine sulfate were used  
 The study was perfomed at Center of 
Anestheisa and Surgical intensive care, Viet Duc 
hospital from March to September of 2018. Convenience 
sampling with 35 patients in each group, and patients 
were ramdomly assigned into group SUGA or NEO/ 
ATR by ballot when they were in operation center. 
 
 Research process 
 Preparing patients included: Anesthesia 
examination, explaining to patients about anesthesia 
Basic and Clinical Medical Researches in Vietnam 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
4422                                                                                                                                                                                              https://www.id-press.eu/mjms/index 
 
method and research. After ASA standard monitoring 
was applied, induction was carried out with fentanyl 
1.5 mcg/kg, propofol 2 mg/kg, rocoronium 0.6 mg/kg, 
then an endotracheal tube was intubated when the 
TOF was 0. Anesthesia was maintained by 
sevoflurane at the MAC of 1-1.5 and intraoperative 
TOF was observed, additional dose of rocuronium 
(0.15 mg/kg) was utilised when TOF count reached 2 
out of 4. TOF value after surgery was recorded right 
after operation. The patients were reversed 
neuromuscular blockade when TOF count > 0: Group 
SUGA (n = 35) was reversed with sugammadex 2 
mg/kg, group NEO/ATR (n = 35) was reversed with 
neostigmine at different doses based on TOF Scan 
which were 60; 50; 40; 30 mcg/kg to TOF value of 
1;2;3;4 respectively [10] and neostigmine was 
combined with atropine at ratio of 3:1. The TOF 
values were recorded at the time of blockade reversal, 
after reversal every minute until 20 minutes and then 
at 30 minutes and 60 minutes. Endotracheal tube 
extubation was performed when patients met criteria 
of full awareness; heart rate < 100 bpm; systolic blood 
pressure > 90mmHg; respiratory rate 10-12 rates/min; 
SpO2 > 95%; body temperature >35.5
0
C; TOF ratio ≥ 
0.9 [11]. 
 
 Analyzing data 
 The research data was analyzed and 
processed by SPSS 20.0 software. Quantitative 
variables were described in average and standard 
deviations. Qualitative variables were described in 
percentage (%). Chi square, T-test with 95% 
confidence, the difference was statistically significant 
when p <0.05. 
 
 
Results 
 
 Common features of study groups 
 Of 70 patients assessed for eligibility, 35 
patients were randomly allocated to two groups. There 
are no significant differences in baseline 
characteristics between 2 groups such as gender, 
age, BMI, hemoglobin concentration or serum 
electrolyte (Table 1). 
Table 1: Patients demographic 
Features Group SUGA 
(n = 35) 
Group NEO/ATR 
(n = 35) 
P 
Gender (male/female) 28/7 25/10  
 
 
 
> 0.05 
Age (yrs): X ± SD 33 ± 7.37 31.83 ± 7.70 
BMI (kg/m²): X ± SD 21.86 ± 3.39 20.77 ± 2.32 
Hemoglobin: X ± SD 147.09 ± 9.81 147.17 ± 9.82 
Serum sodium (mmol/l): X ± SD 136.8 ± 1.98 136.66 ± 2.04 
Serum potassium (mmol/l): X ± SD 3.88 ± 0.33 3.82 ± 0.30 
Serum calcium (mmol/l): X ± SD 2.30 ± 0.12 2.27 ± 0.11 
Serum creatinine (mmol/l): X ± SD 80.69 ± 14.20 81.66 ± 13.28 
Serum albumin (mmol/l): X ± SD 45.49 ± 2.67 44.58 ±2.58 
Blood loss (ml): X ± SD 114.29 ± 53.64 118.57 ± 40.38 
  
 In our study, the rate of right kidney collection 
in group I was 60% and group II was 71.4%, there 
was no significant difference in the two groups (p> 
0.05). The average anesthesia time of group I was 
178.43 ± 36.54 minutes and group II was 171.43 ± 
25.71 minutes, this time of the two groups did not 
differ significantly (p > 0.05). The average amount of 
blood loss between the two groups was not 
statistically significant with p > 0.05. 
 
 Anesthesia time and medication used in 
 surgery 
 The total amount of propofol, fentanyl and 
sevoflurane used to induce and maintain anesthesia 
in the two groups were matching. The average 
rocuronium used in group I, II are the same which are 
76.15 ± 17.78 mg and 71.20 ± 11.53 respectively. 
There was no difference in the total amount of 
rocuronium used as well as the quantity of rocuronium 
in the last 45 minutes of the operation and the 
repeated dose of rocuronium of the two groups (p> 
0.05) (Table 2). 
Table 2: Characteristics of drugs used in surgery 
Group 
Index 
Group I 
(n = 35) 
Group II 
(n = 35) 
P 
Fentanyl (mg) 0.21 ± 0.05 0.9 ± 0.04 
> 0.05 
Propofol (mg) 125.71 ± 24.53 117.74 ± 18.43 
Sevoflurane (ml) 29.69 ± 6.69 28.14 ± 6.95 
Rocuronium (mg) 76.15 ± 17.78 71.20 ± 11.53 
Rocuronium used in the last 45 min (mg) 9.0 ± 2.56 8.17 ± 2.68 
Times of repeating rocuronium 3.14 ± 0.73 3.17 ± 0.66 
  
 Postoperative indexes 
 Patients were monitored at the end of surgery 
the temperature; MAC (Minimum aveolar 
concentration) and Et Sevoflurane (expiratory 
sevoflurane concentration). The temperature at the 
end of surgery in group SUGA was 36.42 ± 0.37
0
C 
which is 36.41 ± 0.37
0
C in group NEO/ATR. MAC got 
to 0.44 ± 0.07 and 0.43 ± 0.06 in group SUGA and 
NEO/ATR. The expiratoty Sevoflurane concentration 
of group SUGA is 0.5 ± 0.06 comparing to 0.47 ± 0.07 
in group NEO/ATR. All showed no differences with p 
value > 0.05 
 
 Rate of TOF ≥ 0.7 and ≥ 0.9 after reversal of 
 NMBAs over time 
 After 2 minutes of reversal: 94.3% of patients 
in group SUGA achieved TOF ≥ 0.7, while only 31.4% 
of patients achieved TOF ≥ 0.7 in group NEO/ATR, 
the variance was statistically substantial with p <0.05. 
After 4 minutes of reversal: 100% patients of group 
SUGA achieved TOF ≥ 0.7, which statistically 
significantly distinguished from 65.7% in group 
NEO/ATR with p < 0.05. After 7 minutes of reversal: 
100% of patients in both study groups achieved TOF 
≥ 0.9 (Figure 1). 
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Figure 1: The ratio reaches TOF 0.7 after reversal of NMBAs over 
time 
 
 After 3 minutes of reversal: group SUGA had 
91.4% patients achieving TOF ≥ 0.9, contrasting with 
only 28.6% patients in group NEO/ATR and the 
difference was also statistically significant with p <0.05 
. After 5 minutes of reversal: 100% patients in group I 
gained TOF ≥ 0.9, whereas in group II only 40% of 
patients obtained TOF ≥ 0.9 and the mismatch was 
also substantial with p <0.05. After 10 minutes of 
reversal: 100% patients in the two study groups 
acquired TOF ≥ 0.9 (Figure 2). 
 
Figure 2: The ratio reaches TOF ≥ 0.9 after reversal of NMBAs over 
time 
 
 Time to TOF ≥ 0.7; ≥ 0.9 and time to 
 extubation 
 Time from starting reversing neuromuscular 
block to reach TOF ≥ 0.7 and TOF ≥ 0.9 in group I is 
faster signigicantly than the one in group II with p 
<0.05 (Table 3). 
Table 3: Time to TOF ≥ 0.7; ≥ 0.9 and time to extubation 
Group 
Time (second) 
Group I 
(n = 35) 
Group II 
(n = 35) 
p 
Time to TOF ≥ 0.7 
  
 
± SD 107.57 ± 54.87 215.57 ± 81.76 <0.05 
Min – Max 30-300 75-435 
 
Time to TOF ≥ 0.9    
± SD 155.29 ± 62.51 313.29 ± 105.77 <0.05 
Min – Max 45-360 120-570 
 
Time to extubation after NMBAs 
reveral  
249.43 ± 81.75 456.29 ± 146.45 <0.05 
 
 
 
 Side effects of NMBAs reversal 
 Sugammadex did not cause changes in the 
heart rate and blood pressure as well as other side 
effects, while heart rate was recorded to decrease in 
the neostigmine and atropine group. There were 2.9% 
patients experiencing xerostomia, 2.9% patients 
undergoing headaches in sugammadex group. In 
group used combination of neostigmine and atropine: 
28.5% patients had bradycardia; 25.7% increased 
phlegm production; 11.4% suffered xerostomia; 11.4% 
had headaches; 22.9% represented nausea. Among 
them, bradycardia, increased secretion of mucus, and 
nausea were statistically significantly different from 
group S with p <0.05. All patients in both groups had 
neither arrhythmias nor bronchospasm. 28.5% 
patients with bradycardia were sinus one (Table 4).  
Table 4: Side effects 
Group 
Side effect 
Group I 
n (%) 
Group II 
n (%) 
P 
Nausea 1(2.9) 8(22.9) <0.05 
Bradycardia 0 10(28.5) <0.05
 
Increased phlegm production 0 9(25.7) <0.05
 
Xerostomia  1(2.9) 4(11.4) >0.05
 
Headache 1(2.9) 4(11.4) >0.05 
  
 
 
Discussion 
 
 The patients in the two study groups did not 
differ in terms of common characteristics: patient age, 
height, weight, BMI classification. As far as surgical 
type, perioperative used drugs, postoperative 
parameters, arterial blood gas of the two groups were 
concerned, there were not significant difference. 
 In the regard of the effect of neuromuscular 
blockade reversal agent, the results of the study 
showed that the group of patients receiving dose of 2 
mg/kg sugamadex had a significantly faster recovery 
time of TOF compared with the patients receiving the 
combination of neostigmine and atropine at the ratio 
3:1. The dose of sugammadex or neostigmine was 
adjusted according to TOF count value mearsured 
right after operation. In the study, time to start 
reversing neuromuscular blockade was when there 
was at least one twitch of TOF [12]. Acorrding to 
Hristovska’s study, time to get TOF 0.9 when reversed 
by sugammadex is significantly faster than that by 
neostigmine at every different dose in patients who 
were maintained by either intravenous anesthetics or 
volatile agents during anesthesia [13]. After 3 minutes 
of sugammadex injection, 91.4% patients achieved 
TOF ≥ 0.9, whereas only 28.6% of patients obtained 
TOF ≥ 0.9 after 4 minutes of neostigmine injection, 
this difference was statistically significant with p <0.05. 
After 5 minutes of reversal, 100% patients of group I 
achieved TOF ≥ 0.9, while the figure for group 2 was 
40%. 
 Neostigmine is a neuromuscular blockade 
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reversal agent that has been used for a long time and 
is clinically popular. The drug causes inactivation of 
acetyl cholinesterase through the irreversible 
carbamylation process. Neostigmine cannot resolve 
the muscle relaxant when the neuromuscular 
blockade is deep. Neostigmine's neuromuscular 
blockade reversal effect usually initiates in about 1-2 
minutes and reaches maximum within 6-10 minutes, 
so it takes about 10 minutes for neostigmine to fully 
perform [14],[15]. In our study, the group treated with 
neostigmine combined with atropine had an average 
recovery time of TOF ≥ 0.7 was 215.57 ± 81.76 
seconds, the slowest recovery time of TOF ≥ 0.7 was 
435 seconds; the average recovery time of TOF ≥ 0.9 
was 313.29 ± 105.77 seconds, the latest was after 
570 seconds. In this group, the number of patients 
who received neostigmine when there was 1-2-3-4 
stimulating response (TOF 1/4) was 4-13-7-11 
respectively. In our study, the time to achieve TOF ≥ 
0.9 was shorter than that of Manfred, Blobner [16], 
and Tiffany Woo [17], Cheong Ho [18]; in the study of 
Blobner and plus, the average recovery time of TOF ≥ 
0.7 is 7.2 minutes, recovery of TOF ≥ 0.9 is 18.6 
minutes. This difference may be due to the fact that 
Blobner and Woo administered reversal agent at the 
time of TOF =2/4, while we injected reversal agent at 
times of different TOF values. In our study, patients 
who recieved neuromuscular blockade reversal at the 
time of TOF=2/4 had average recovery time of TOF ≥ 
0.7 and TOF ≥ 0.9 was 238.85 ± 80.89 seconds and 
339.23 ± 115.80 seconds respectively. This result is 
longer than that of Wu Xinmin [19], this difference can 
be attributed to the fact that we used sevofluran for 
anaesthesia maintenance. Sevofluran has been 
shown to slow neostigmine's muscle relaxant recovery 
[20]. 
 Sugammadex was approved for use in 
Europe in 2008 by the European, Pharmaceutical 
Authorities. In 2015, sugammadex was accepted by 
the American Pharmaceutical Society, and now it has 
been used in 70 countries [21]. With the mechanism 
of direct action through rapid chemical interaction, 
sugammadex forms a stable complex with non-
depolarizing muscle relaxants. Sugammadex 16 
mg/kg can be used in case of rescue when intubation 
is not possible after 1.2 mg/kg rocuronium injected, 
TOF achieved the value of ≥ 0.9 after 2 - 3 minutes 
[22]. In our study, we used dose of 2mg/kg 
sugammadex for all TOF count values. The results 
showed that after sugammadex injection, average 
time of TOF achieved ≥ 0.7 was 107.57 ± 54.87 
seconds; and TOF ≥ 0.9 was 155.29 ± 62.51 seconds. 
The fastest time to recover TOF ≥ 0.7 was 0.30; and 
the fastest time to reach TOF ≥ 0.9 was 45 seconds. 
In this group, the number of patients receiving 
neuromuscular blockade reversal agent at the 
moment of TOF count = 1-2-3-4 stimulus response 
was 15-14-5-1 respectively. In patients who were 
reversed at TOF score of 2 stimuli, the average 
recovery time of TOF ≥ 0.7 and TOF ≥ 0.9 was 84.64 
± 24.67 seconds and 136.43 ± 32.10 seconds, 
correspondingly. Our results was similar to other 
studies, which showed that sugammadex can quickly 
dissolves rocuronium molecule: the average time of 
TOF ≥ 0.9 was 155.29 seconds; after 3 minutes, 
91.4% patients recovered TOF ≥ 0.9; after 5 minutes, 
100% patients recover TOF ≥ 0.9. 
 In the regard of undesirable effects: The rate 
of patients with bradycardia, nausea, and increased 
secretion of group 2 was significantly higher than 
group I, this result is shown in Table 3.7. Group 2 had 
10 patients with heart rate <50 beats/minute 
accounting for 28.5%, 9 patients had increased 
sputum secretion mounting to 25.7%, 4 patients with 
dry mouth and 4 patients with headache occupying 
11.4% and 8 patients (22.9%) had nausea. On the 
contrary, Group I had only 1 patient with headache, 1 
patient with nausea, 1 patient with xerostomia, each 
accounting for 2.9%. In our study, we did not see any 
patients with allergies, dizziness, hypotension ... after 
reversal. Nausea and vomiting are common concern 
after surgery. There are many factors that are thought 
to be related to postoperative vomiting and nausea 
such as laparoscopic surgery with 
pneumoperitoneum, usage of atropine for 
neuromuscular blockade reversal compared to 
patients without postoperative reversal (68% vs. 32%) 
[23]. In our study, we had 8 patients (22.9%) with 
nausea in group II, including 2 patients had severe 
nausea, this patient was given metoclopramide 10 mg 
intravenously, and responded well to treatment. In the 
group of using sugammadex for neuromuscular 
blockade reversal there was 1 patients (2.9%) who 
suffered from nausea and vomiting after surgery. 
Some other studies recorded the rate of postoperative 
nausea and vomiting in patients with neuromuscular 
blockade reversal by sugammadex: Blobner 4%, 
Tiffany Woo 7%, Yazar 5%; [16], [17], [22]. We did not 
document any patients with bronchospasm after 
extubation. But 25.7% patients in group II increased 
sputum production, whilst in group I there was no 
patient with this symtom. Emine Yazar noted that 2 
patients (3.4%) had bronchospasm after 
neuromuscular blockade reversal with sugammadex, 
but the author did not describe these two cases [22]. 1 
patient (2.9%) in group I and 4 patients (11.4%) in 
group II had headache after surgery, there was no 
difference between the two groups, p > 0.05. In 
Tiffany Woo's study, the headache rate of 
neuromuscular blockade reversal with sugammadex 
and neostigmine was 12% and 15% respectively [11]. 
The rate of dry mouth in group II was 11.4%; group I 
is 2.9%. Xerostomia in patients receiving 
neuromuscular blockade reversal with neostigmine 
are associated with the use of combined atropine. In 
addition, the evaluation of this symptom is also 
difficult, because the patient must fast to prepare for 
surgery, so the patient had a feeling of dry mouth 
before. In the Blobner study, the rate of dry mouth 
was 6% in both groups used neostigmine and 
sugammadex [16]. 
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 The objects of our study were patients who 
experienced laparoscopic nephrectomy, so it is 
necessary to monitor and evaluate plasma creatinine 
level before and after 24 hour of surgery which were 
shown to be not significantly different between the two 
groups. 
 In conclusion, Sugammadex has better 
neuromuscular block reversal effects than 
neostigmine. Recovery time reaching TOF ≥ 0.9 of 
group using sugammadex 2mg/kg is significantly 
faster than the one of group using neostigmine 
combined with atropine at the rate of 3:1 following 
TOF count. Sugammadex also reduces side effects 
induced by neuromuscular blockade reversal agents 
in living donor nephrectomy surgery. 
 
 
Ethical approval 
 
 All procedures performed in studies involving 
human participants were in accordance with the 
ethical standards of institutional and/or national 
research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable 
ethical standards. The study has been approved by 
Science and Medical Ethics Review Board of Viet Duc 
hospital and Committee of Science and Ethics of 
Hanoi Medical University. 
 
 
Informed consent 
 
 The patient's family was fully explained about 
the research process and agreed to participate. Risk 
patients had been excluded to minimize the unwanted 
effects of monitoring methods. Information about 
medical records and images were kept confidentially. 
Informed consents were obtained from the patients 
included in the study. 
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